Premium
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques
Author(s) -
Arnold Douglas L.,
Matthews Paul M.,
Francis Gordon S.,
O'Connor John,
Antel Jack P.
Publication year - 1992
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410310302
Subject(s) - choline , creatine , magnetic resonance imaging , lesion , medicine , nuclear magnetic resonance , nuclear medicine , pathology , central nervous system disease , proton magnetic resonance , pathological , radiology , physics
We used proton magnetic resonance (MR) spectroscopic imaging to determine the serial changes in MR signals from choline, creatine, lactate, and N ‐acetylaspartate in and around a large demyelinating lesion followed over a period of 8 months. Elevated lactate and choline signals were observed at the first examination 3 days after the onset of symptoms. Reduced N ‐acetylaspartate signals were observed a few days afterward. The abnormals metabolite signals varied in different regions of the lesions and extended beyound the borders of abnormal signal intensity seen on conventional MR imaging (MRI). On the last examination at 8 months when the lesion appeared much smaller on MRI, choline signals from the center of the lesions were still high, but were falling. Choline signals outside the lesions on MRI had returned to normal as had lactate signals everywhere. Importantly, there was no recovery of N ‐acetylasparatate signals in or adjaccent to the lesion on MRI. This serial study demonstrates the potential of MR spectroscopic imaging for characterizing the chemical pathological evolution of demyelinating lesions in ways that conventional MRI cannot. We propose that abnormal signals from choline can indicate recent regional demyelination, while persistent abnormal signals from N ‐acetylaspartate can provide an index of irreversible damage in the nervous system.